BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 22872738)

  • 1. Usefulness of 3'-deoxy-3'-18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer.
    Kishino T; Hoshikawa H; Nishiyama Y; Yamamoto Y; Mori N
    J Nucl Med; 2012 Oct; 53(10):1521-7. PubMed ID: 22872738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in (18)F-fluorothymidine and (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy.
    Hoshikawa H; Mori T; Kishino T; Yamamoto Y; Inamoto R; Akiyama K; Mori N; Nishiyama Y
    Ann Nucl Med; 2013 May; 27(4):363-70. PubMed ID: 23378102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.
    Hoshikawa H; Mori T; Yamamoto Y; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y
    Clin Nucl Med; 2015 Jun; 40(6):464-8. PubMed ID: 25546204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome.
    Hoeben BA; Troost EG; Span PN; van Herpen CM; Bussink J; Oyen WJ; Kaanders JH
    J Nucl Med; 2013 Apr; 54(4):532-40. PubMed ID: 23345303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
    Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can 3'-Deoxy-3'-((18)F) Fluorothymidine Out Perform 2-Deoxy-2-((18)F) Fluoro-D-Glucose Positron Emission Tomography/Computed Tomography in the Diagnosis of Cervical Lymphadenopathy in Patients With Oral/Head and Neck Cancer?
    Schaefferkoetter JD; Carlson ER; Heidel RE
    J Oral Maxillofac Surg; 2015 Jul; 73(7):1420-8. PubMed ID: 25869746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the diagnostic value of 3-deoxy-3-18F-fluorothymidine and 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the assessment of regional lymph node in thoracic esophageal squamous cell carcinoma: a pilot study.
    Han D; Yu J; Zhong X; Fu Z; Mu D; Zhang B; Xu G; Yang W; Zhao S
    Dis Esophagus; 2012 Jul; 25(5):416-26. PubMed ID: 21951837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
    Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
    Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer.
    Ong SC; Schöder H; Lee NY; Patel SG; Carlson D; Fury M; Pfister DG; Shah JP; Larson SM; Kraus DH
    J Nucl Med; 2008 Apr; 49(4):532-40. PubMed ID: 18344440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
    Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
    J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
    Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
    J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accuracy of (18) FDG PET-CT for treatment evaluation 3 months after completion of chemoradiotherapy for head and neck squamous cell carcinoma: 2-year minimum follow-up.
    Sagardoy T; Fernandez P; Ghafouri A; Digue L; Haaser T; de Clermont-Galleran H; Castetbon V; de Monès E
    Head Neck; 2016 Apr; 38 Suppl 1():E1271-6. PubMed ID: 26315809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early prediction of local control in head and neck cancer after chemoradiotherapy by FDG-PET.
    Hoshikawa H; Kishino T; Nishiyama Y; Yamamoto Y; Yonezaki M; Mori N
    Nucl Med Commun; 2011 Aug; 32(8):684-9. PubMed ID: 21709618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3'-deoxy-3'-[¹⁸F]-fluorothymidine PET/CT in early determination of prognosis in patients with esophageal squamous cell cancer: comparison with [¹⁸F]-FDG PET/CT.
    Chen H; Li Y; Wu H; Sun L; Lin Q; Zhao L; An H
    Strahlenther Onkol; 2015 Feb; 191(2):141-52. PubMed ID: 25163419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of 18F-FDG PET/CT and CT/MRI with histopathologic correlation in patients undergoing salvage surgery for head and neck squamous cell carcinoma.
    Kim SY; Kim JS; Yi JS; Lee JH; Choi SH; Nam SY; Cho KJ; Lee SW; Kim SB; Roh JL
    Ann Surg Oncol; 2011 Sep; 18(9):2579-84. PubMed ID: 21409485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of 18F-FLT PET for detecting second primary cancers and distant metastases in head and neck cancer patients.
    Hoshikawa H; Kishino T; Mori T; Nishiyama Y; Yamamoto Y; Mori N
    Clin Nucl Med; 2013 Aug; 38(8):e318-23. PubMed ID: 23455521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy Response Assessment and Patient Outcomes in Head and Neck Squamous Cell Carcinoma: FDG PET Hopkins Criteria Versus Residual Neck Node Size and Morphologic Features.
    Wray R; Sheikhbahaei S; Marcus C; Zan E; Ferraro R; Rahmim A; Subramaniam RM
    AJR Am J Roentgenol; 2016 Sep; 207(3):641-7. PubMed ID: 27341273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measuring tumor cell proliferation with 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study.
    Yue J; Chen L; Cabrera AR; Sun X; Zhao S; Zheng F; Han A; Zheng J; Teng X; Ma L; Ma Y; Han D; Zhao X; Mu D; Yu J; Li Y
    J Nucl Med; 2010 Apr; 51(4):528-34. PubMed ID: 20237030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms.
    Kitagawa Y; Sadato N; Azuma H; Ogasawara T; Yoshida M; Ishii Y; Yonekura Y
    J Nucl Med; 1999 Jul; 40(7):1132-7. PubMed ID: 10405132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical significance of postradiotherapy [18F]-fluorodeoxyglucose positron emission tomography imaging in management of head-and-neck cancer-a long-term outcome report.
    Yao M; Smith RB; Hoffman HT; Funk GF; Lu M; Menda Y; Graham MM; Buatti JM
    Int J Radiat Oncol Biol Phys; 2009 May; 74(1):9-14. PubMed ID: 18930358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.